Zhejiang Medicine Co Ltd banner

Zhejiang Medicine Co Ltd
SSE:600216

Watchlist Manager
Zhejiang Medicine Co Ltd Logo
Zhejiang Medicine Co Ltd
SSE:600216
Watchlist
Price: 15.33 CNY 0.33% Market Closed
Market Cap: ¥14.7B

Zhejiang Medicine Co Ltd
Long-Term Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Zhejiang Medicine Co Ltd
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Zhejiang Medicine Co Ltd
SSE:600216
Long-Term Debt
¥357.6m
CAGR 3-Years
21%
CAGR 5-Years
-7%
CAGR 10-Years
33%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Long-Term Debt
¥47.6m
CAGR 3-Years
-78%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Long-Term Debt
¥43.3m
CAGR 3-Years
-24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Long-Term Debt
¥779.6m
CAGR 3-Years
39%
CAGR 5-Years
84%
CAGR 10-Years
-1%
Zhejiang Nhu Co Ltd
SZSE:002001
Long-Term Debt
¥4.2B
CAGR 3-Years
-7%
CAGR 5-Years
0%
CAGR 10-Years
46%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Long-Term Debt
¥1.2B
CAGR 3-Years
129%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Medicine Co Ltd
Glance View

Market Cap
14.7B CNY
Industry
Pharmaceuticals

Zhejiang Medicine Co., Ltd., a stalwart in the pharmaceutical industry, traces its roots back to a time when China's economic landscape was rapidly transforming. Founded amidst the burgeoning wave of Chinese industrial expansion, the company made a calculated entry into the biopharmaceutical sector, a move that positioned it as an indispensable player in the realm of vitamins and antibiotics. Headquartered in the populous province of Zhejiang, the firm quickly honed its expertise in the manufacturing and export of fat-soluble vitamins, notably vitamin E, which became one of its hallmark products. Their robust production facilities and rigorous adherence to quality standards have not only fueled domestic demand but also secured a strong foothold in international markets, particularly Europe and the Americas. Zhejiang Medicine has crafted a diversified portfolio that spans active pharmaceutical ingredients (APIs) and advanced intermediates, offering a spectrum of products utilized by various health and pharmaceutical companies worldwide. A key revenue driver for the company lies in its vertical integration strategy, which enables it to maintain meticulous oversight over the entire production process, from raw materials to finished goods. The company’s commitment to R&D is evident in its investments in technology and innovation, allowing it to improve production efficiency and develop new compounds that cater to the evolving demands of the health sector. This approach not only insulates the company from market volatility but also fortifies its competitive position in a dynamic industry.

Intrinsic Value
17.11 CNY
Undervaluation 10%
Intrinsic Value
Price ¥15.33

See Also

What is Zhejiang Medicine Co Ltd's Long-Term Debt?
Long-Term Debt
357.6m CNY

Based on the financial report for Dec 31, 2025, Zhejiang Medicine Co Ltd's Long-Term Debt amounts to 357.6m CNY.

What is Zhejiang Medicine Co Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
33%

Over the last year, the Long-Term Debt growth was 109%. The average annual Long-Term Debt growth rates for Zhejiang Medicine Co Ltd have been 21% over the past three years , -7% over the past five years , and 33% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett